We are live on ! Find out more
UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Portfolio holdings

AUM $863M
1-Year Est. Return 30.35%
This Fund
S&P 500
This Quarter Est. Return
+18.86%
1 Year Est. Return
+30.35%
3 Year Est. Return
+68.34%
5 Year Est. Return
+24.17%
10 Year Est. Return
–
AUM
$130M
AUM Growth
-$40.1M
Cap. Flow
-$59.1M
Cap. Flow %
-45.34%
Top 10 Hldgs %
99.1%
Holding
26
New
5
Increased
1
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
EOCW.U
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
+$20M
2
PXD
Pioneer Natural Resource Co.
PXD
+$574K
3
WY icon
Weyerhaeuser
WY
+$37.1K
4
AAPL icon
Apple
AAPL
+$25.9K
5
UNH icon
UnitedHealth
UNH
+$9.97K

Top Sells

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$54M
2
TSHA icon
Taysha Gene Therapies
TSHA
+$18.2M
3
VIR icon
Vir Biotechnology
VIR
+$4.85M
4
DNLI icon
Denali Therapeutics
DNLI
+$1.35M
5
VT icon
Vanguard Total World Stock ETF
VT
+$1.18M

Sector Composition

Rank Sector Weight
1 Healthcare 66.82%
2 Technology 4.74%
3 Energy 0.46%
4 Real Estate 0.03%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSHA icon
1
Taysha Gene Therapies
TSHA
$2.05B
$29.5M 22.62%
1,391,190
-787,810
-36% -$18.2M
BEAM icon
2
Beam Therapeutics
BEAM
$2.76B
$28.9M 22.15%
224,391
+1
+0% +$80
EOCW.U
3
DELISTED
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
$20M 15.36%
+2,000,000
New +$20M
VT icon
4
Vanguard Total World Stock ETF
VT
$81.4B
$16.4M 12.6%
158,484
-11,541
-7% -$1.18M
CDAK
5
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$15.7M 12.04%
847,108
– –
IMTX icon
6
Immatics
IMTX
$1.33B
$8.1M 6.21%
697,431
– –
TXN icon
7
Texas Instruments
TXN
$253B
$6.15M 4.72%
32,000
– –
SYRE icon
8
Spyre Therapeutics
SYRE
$9.18B
$1.88M 1.44%
10,783
-404
-4% -$73.4K
SOLY
9
DELISTED
Soliton, Inc.
SOLY
$1.69M 1.29%
75,000
– –
PLXP
10
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$865K 0.66%
62,673
– –
PXD
11
DELISTED
Pioneer Natural Resource Co.
PXD
$594K 0.46%
+3,656
New +$574K
TFFP
12
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
$212K 0.16%
883
– –
LXRX icon
13
Lexicon Pharmaceuticals
LXRX
$1.05B
$164K 0.13%
35,714
– –
APEN
14
DELISTED
Apollo Endosurgery, Inc.
APEN
$126K 0.1%
15,601
– –
WY icon
15
Weyerhaeuser
WY
$17.8B
$34K 0.03%
+1,000
New +$37.1K
AAPL icon
16
Apple
AAPL
$4.41T
$27K 0.02%
+200
New +$25.9K
UNH icon
17
UnitedHealth
UNH
$364B
$10K 0.01%
+25
New +$9.97K
POR icon
18
Portland General Electric
POR
$5.74B
$5K ﹤0.01%
118
– –
AMZN icon
19
Amazon
AMZN
$2.88T
– –
-60
Closed -$9K
DNLI icon
20
Denali Therapeutics
DNLI
$4.04B
– –
-23,629
Closed -$1.35M
META icon
21
Meta Platforms (Facebook)
META
$1.47T
– –
-180
Closed -$53K
PG icon
22
Procter & Gamble
PG
$335B
– –
-20
Closed -$3K
TPL icon
23
Texas Pacific Land
TPL
$23.6B
– –
-144
Closed -$25K
UPS icon
24
United Parcel Service
UPS
$88.4B
– –
-200
Closed -$34K
VIR icon
25
Vir Biotechnology
VIR
$1.52B
– –
-94,513
Closed -$4.85M
1
2

Similar funds

WFAL
Wedbush Fund Advisers, LLC Pasadena, California $863M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
OMG
One Madison Group New York $866M AUM 33.81% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
RWM
RMG Wealth Management Platteville, Wisconsin $866M AUM 11.95% 1-Year Est. Return
BCM
Benchstone Capital Management New York $860M AUM 32.46% 1-Year Est. Return
HP
Havemeyer Place Greenwich, Connecticut $867M AUM
OAM
Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s Q2 2021 Portfolio in Review

As of Q2 2021, University of Texas/Texas AM Investment Management Co (UTIMCO) held 26 positions worth $130M, down 24% from $170M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

University of Texas/Texas AM Investment Management Co (UTIMCO) withdrew a net $59.1M in Q2 2021, closing 8 positions and reducing 3 holdings. Its most notable exit was Accolade Inc, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 55% a quarter earlier, followed by Technology and Energy.

Against the trend, University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant worth $20M.

  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s largest Q2 2021 buy was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 2,000,000 shares worth $20M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) added most to Beam Therapeutics in Q2 2021, an estimated $80 increase.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s biggest Q2 2021 reduction was Taysha Gene Therapies, cutting an estimated $18.2M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) fully exited Accolade Inc in Q2 2021, selling an estimated $54M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s ten largest holdings make up 99% of its $130M portfolio in Q2 2021.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) opened 5 new positions and closed 8 in Q2 2021.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio value fell 24% quarter-over-quarter to $130M.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2021, filed 6 Aug 2021.